Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-28 9:47 pm Purchase |
2025-03-25 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 1,028,086 27.900% |
187,187 (+22.26%) |
Filing History |
| 2025-02-12 3:36 pm Sale |
2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
MFN Partners, LP | 0 0.000% |
-121,384 (Position Closed) |
Filing History |
| 2025-02-12 1:25 pm Purchase |
2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
American Endowment Foundation | 133,026 4.910% |
133,026 (New Position) |
Filing History |
| 2025-02-12 09:28 am Sale |
2024-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
FMR CORP | 4,740 0.200% |
-158,109 (-97.09%) |
Filing History |
| 2024-12-06 4:05 pm Sale |
2024-11-30 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Slate Path Capital LP | 0 0.000% |
-357,880 (Position Closed) |
Filing History |
| 2024-07-12 6:17 pm Sale |
2024-07-12 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Artal Participations S.a r.l | 116,155 4.300% |
-22,800 (-16.41%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
TYNDALL CAPITAL PARTNERS L P | 164,429 6.700% |
42,791 (+35.18%) |
Filing History |
| 2024-02-09 5:06 pm Sale |
2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Artal Participations S.a r.l | 138,955 5.700% |
-1 (-0.00%) |
Filing History |
| 2024-02-09 08:50 am Purchase |
2024-02-08 | 13G | Cyclerion Therapeutics, Inc. CYCN |
FMR CORP | 162,849 6.660% |
162,849 (New Position) |
Filing History |
| 2024-01-22 3:44 pm Purchase |
2023-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Slate Path Capital LP | 357,880 14.600% |
357,880 (New Position) |
Filing History |
| 2023-12-05 4:00 pm Purchase |
2023-11-30 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 840,899 26.900% |
322,435 (+62.19%) |
Filing History |
| 2023-09-05 4:05 pm Purchase |
2023-08-23 | 13G | Cyclerion Therapeutics, Inc. CYCN |
TYNDALL CAPITAL PARTNERS L P | 121,638 5.050% |
121,638 (New Position) |
Filing History |
| 2023-05-23 4:00 pm Purchase |
2023-05-19 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 518,464 19.990% |
518,464 (New Position) |
Filing History |
| 2023-05-12 08:39 am Purchase |
2023-05-11 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 518,465 19.990% |
307,482 (+145.74%) |
Filing History |
| 2023-04-03 07:30 am Purchase |
2023-03-31 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 210,983 9.200% |
980 (+0.47%) |
Filing History |
| 2023-02-09 09:59 am Purchase |
2023-02-09 | 13G | Cyclerion Therapeutics, Inc. CYCN |
FMR CORP | 171,048 7.865% |
40,178 (+30.70%) |
Filing History |
| 2023-01-13 4:30 pm Unchanged |
2022-11-01 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Slate Path Capital LP | 357,880 16.500% |
0 (Unchanged) |
Filing History |
| 2022-11-21 5:00 pm Purchase |
2022-11-20 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Peter M. Hecht | 210,003 9.200% |
30,169 (+16.78%) |
Filing History |
| 2022-10-21 5:13 pm Unchanged |
2022-10-21 | 13D | Cyclerion Therapeutics, Inc. CYCN |
Slate Path Capital LP | 357,880 16.500% |
0 (Unchanged) |
Filing History |
| 2022-02-11 4:41 pm Purchase |
2021-12-31 | 13G | Cyclerion Therapeutics, Inc. CYCN |
Slate Path Capital LP | 357,880 16.490% |
48,077 (+15.52%) |
Filing History |